(Q46955645)

26 December 2017

title

Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. (English)

1 reference

26 December 2017

1 reference

1 reference

multiple drug resistance

1 reference

1

1 reference

26 December 2017

Margaret A Fischl

5

object named as

Margaret A Fischl

1 reference

26 December 2017

author name string

Daniel Brazeau

2

1 reference

26 December 2017

Barry S Zingman

3

1 reference

26 December 2017

Richard C Reichman

4

1 reference

26 December 2017

Barbara M Gripshover

6

1 reference

26 December 2017

Charles S Venuto

7

1 reference

26 December 2017

Judianne C Slish

8

1 reference

26 December 2017

Robin DiFrancesco

9

1 reference

26 December 2017

Alan Forrest

10

1 reference

26 December 2017

Gene D Morse

11

1 reference

26 December 2017

publication date

1 March 2007

1 reference

26 December 2017

published in

Pharmacogenomics

1 reference

26 December 2017

volume

8

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

page(s)

227-235

1 reference

26 December 2017

Therapeutic drug monitoring in HIV infection: current status and future directions

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Therapeutic drug monitoring in the treatment of HIV-infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Critical issues in therapeutic drug monitoring of antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Atazanavir for the treatment of human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Low initial trough plasma concentrations of lopinavir are associated with an impairment of virological response in an unselected cohort of HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Identification of functionally variant MDR1 alleles among European Americans and African Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

No influence of the P-glycoprotein polymorphisms MDR1 G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Reverse phase high-performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

P glycoprotein in human immunodeficiency virus type 1 infection and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Frequency of C3435T polymorphism of MDR1 gene in African people

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

HIV-protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

The role of clinical pharmacology in optimizing antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.8.3.227

21 January 2018

Identifiers

DOI

10.2217/14622416.8.3.227

1 reference

26 December 2017

PubMed ID

17324111

1 reference

26 December 2017